Index -
P/E -
EPS (ttm) -1.92
Insider Own 26.27%
Shs Outstand 51.65M
Perf Week 11.98%
Market Cap 309.40M
Forward P/E -
EPS next Y -1.79
Insider Trans 0.00%
Shs Float 38.73M
Perf Month 20.20%
Income -82.44M
PEG -
EPS next Q -0.43
Inst Own 67.12%
Short Float 4.54%
Perf Quarter 103.10%
Sales 0.00M
P/S -
EPS this Y 8.95%
Inst Trans 0.10%
Short Ratio 2.73
Perf Half Y 208.38%
Book/sh 2.26
P/B 2.61
EPS next Y -4.49%
ROA -52.37%
Short Interest 1.76M
Perf Year 300.68%
Cash/sh 2.50
P/C 2.35
EPS next 5Y -
ROE -70.94%
52W Range 1.43 - 6.85
Perf YTD 109.61%
Dividend Est. -
P/FCF -
EPS past 5Y -49.79%
ROI -59.34%
52W High -14.01%
Beta 2.60
Dividend TTM -
Quick Ratio 6.82
Sales past 5Y 0.00%
Gross Margin -
52W Low 311.89%
ATR (14) 0.44
Dividend Ex-Date -
Current Ratio 6.82
EPS Y/Y TTM 23.34%
Oper. Margin 0.00%
RSI (14) 62.60
Volatility 8.39% 8.18%
Employees 54
Debt/Eq 0.22
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 12.80
Option/Short Yes / Yes
LT Debt/Eq 0.19
EPS Q/Q 35.12%
Payout -
Rel Volume 0.88
Prev Close 5.11
Sales Surprise -
EPS Surprise 27.04%
Sales Q/Q -
Earnings Mar 12 BMO
Avg Volume 644.93K
Price 5.89
SMA20 13.86%
SMA50 20.06%
SMA200 69.22%
Trades
Volume 566,432
Change 15.26%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-14-23 Initiated
Piper Sandler
Overweight
Jun-30-23 Upgrade
Stifel
Hold → Buy
$2 → $10
Jun-28-23 Upgrade
H.C. Wainwright
Neutral → Buy
$11
Jun-27-23 Upgrade
Wedbush
Neutral → Outperform
$10
Mar-29-22 Downgrade
Wedbush
Outperform → Neutral
Mar-22-22 Downgrade
H.C. Wainwright
Buy → Neutral
Sep-30-21 Initiated
Stifel
Hold
$10
Jan-07-21 Initiated
Wedbush
Outperform
$45
Nov-24-20 Initiated
Berenberg
Buy
$58
May-04-20 Initiated
H.C. Wainwright
Buy
$53
Feb-24-20 Initiated
JP Morgan
Overweight
$42
Feb-24-20 Initiated
Jefferies
Buy
Feb-24-20 Initiated
Cowen
Outperform
Feb-24-20 Initiated
Canaccord Genuity
Buy
$50
Show Previous Ratings
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
09:55AM
Loading…
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
(Associated Press Finance) -5.50%
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
07:00AM
Loading…
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
(Associated Press Finance)
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
(American City Business Journals)
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
(Associated Press Finance)
07:30AM
07:43AM
Loading…
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
07:30AM
Feb-27-23 08:00AM
Feb-15-23 05:46AM
Jan-19-23 05:41AM
Jan-05-23 08:00AM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-09-22 09:35AM
09:04AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-26-22 08:00AM
Sep-06-22 08:00AM
Aug-28-22 09:41AM
Aug-09-22 08:00AM
Aug-03-22 08:00AM
Aug-01-22 08:55AM
Jul-02-22 08:29AM
Jun-06-22 08:00AM
Jun-01-22 07:00AM
May-17-22 07:00AM
May-12-22 04:30PM
May-11-22 04:30PM
Apr-28-22 12:52PM
(American City Business Journals)
Apr-25-22 09:00AM
Apr-18-22 07:00AM
Apr-07-22 04:30PM
07:00AM
Mar-17-22 05:00PM
Mar-02-22 08:00AM
Feb-22-22 08:00AM
Feb-16-22 05:28AM
Jan-11-22 07:00AM
Jan-10-22 07:00AM
Jan-05-22 08:00AM
Nov-18-21 05:27AM
Nov-08-21 04:05PM
07:45AM
Oct-08-21 04:05PM
Oct-04-21 11:02AM
Sep-30-21 04:35PM
Sep-21-21 04:05PM
07:45AM
Aug-12-21 08:22AM
Aug-10-21 07:45AM
Aug-04-21 07:45AM
Aug-02-21 02:26AM
Jul-29-21 03:53PM
May-19-21 05:00PM
May-17-21 07:45AM
May-07-21 07:45AM
May-04-21 02:01AM
Apr-28-21 10:38AM
Apr-10-21 08:30AM
Mar-25-21 07:45AM
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BIOTECH GROWTH N V 10% Owner Oct 17 '23 Buy 2.34 400,000 934,080 8,517,839 Oct 19 03:08 PM Behbahani Ali Director Jul 05 '23 Buy 5.00 1,000,000 5,000,000 4,448,757 Jul 06 04:45 PM RA CAPITAL MANAGEMENT, L.P. Director Jul 05 '23 Buy 5.00 935,850 4,679,250 3,213,828 Jul 07 04:30 PM BIOTECH GROWTH N V 10% Owner Jun 30 '23 Buy 5.00 1,000,000 5,000,000 8,117,839 Jul 03 03:36 PM BIOTECH GROWTH N V 10% Owner Jun 27 '23 Buy 5.49 1,740,000 9,555,036 7,117,839 Jun 29 01:37 PM Epstein David M. SEE REMARKS Jun 27 '23 Sale 6.70 25,000 167,500 671,423 Jun 28 04:02 PM
Index -
P/E -
EPS (ttm) -0.59
Insider Own 2.27%
Shs Outstand 44.10M
Perf Week -3.80%
Market Cap 268.98M
Forward P/E -
EPS next Y -1.05
Insider Trans 3.20%
Shs Float 43.25M
Perf Month -28.97%
Income -25.80M
PEG -
EPS next Q -0.19
Inst Own 78.62%
Short Float 1.78%
Perf Quarter -21.95%
Sales 0.00M
P/S -
EPS this Y -31.33%
Inst Trans -11.39%
Short Ratio 6.02
Perf Half Y 50.31%
Book/sh 3.19
P/B 1.91
EPS next Y -32.74%
ROA -16.68%
Short Interest 0.77M
Perf Year 126.02%
Cash/sh 3.21
P/C 1.89
EPS next 5Y -
ROE -17.05%
52W Range 2.56 - 11.67
Perf YTD -7.88%
Dividend Est. -
P/FCF -
EPS past 5Y 25.04%
ROI -18.31%
52W High -47.90%
Beta 1.77
Dividend TTM -
Quick Ratio 40.75
Sales past 5Y 0.00%
Gross Margin -
52W Low 137.50%
ATR (14) 0.63
Dividend Ex-Date -
Current Ratio 40.75
EPS Y/Y TTM 21.28%
Oper. Margin 0.00%
RSI (14) 25.12
Volatility 9.73% 8.90%
Employees 50
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 19.00
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 11.63%
Payout -
Rel Volume 1.40
Prev Close 6.12
Sales Surprise -
EPS Surprise 16.67%
Sales Q/Q -
Earnings Feb 13 BMO
Avg Volume 127.72K
Price 6.08
SMA20 -18.70%
SMA50 -27.28%
SMA200 5.93%
Trades
Volume 178,467
Change -0.65%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-26-23 Resumed
Oppenheimer
Outperform
$17
Mar-04-21 Initiated
Piper Sandler
Overweight
$50
Jan-11-21 Reiterated
H.C. Wainwright
Buy
$10 → $17
Nov-02-20 Initiated
Jefferies
Buy
$17
Oct-25-19 Initiated
Oppenheimer
Outperform
$8
Apr-09-24 08:00AM
Mar-07-24 08:13PM
Feb-26-24 01:14PM
Feb-14-24 04:35AM
Feb-13-24 07:25AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Feb-07-24 08:47PM
Feb-06-24 08:00AM
Jan-25-24 10:00AM
Dec-21-23 04:13PM
Dec-12-23 12:03PM
09:12AM
07:20AM
(Associated Press Finance)
07:00AM
Nov-23-23 11:05AM
08:00AM
Loading…
Nov-21-23 08:00AM
Nov-08-23 08:00AM
Nov-06-23 05:51PM
Oct-30-23 10:59AM
Oct-26-23 05:41PM
Oct-21-23 09:00AM
Sep-18-23 07:00AM
Aug-31-23 07:00AM
Aug-14-23 08:43AM
Aug-08-23 07:17AM
(Associated Press Finance)
07:00AM
Jun-06-23 07:00AM
Jun-01-23 07:00AM
May-24-23 11:04AM
May-18-23 06:25AM
(Zacks Small Cap Research)
07:00AM
Loading…
May-11-23 07:00AM
May-09-23 07:19AM
07:00AM
Apr-18-23 07:00AM
Apr-12-23 07:00AM
Mar-08-23 07:00AM
Mar-07-23 05:19AM
Feb-23-23 05:43AM
(Zacks Small Cap Research)
Feb-13-23 05:00PM
Feb-07-23 07:00AM
Feb-02-23 04:01PM
Jan-25-23 05:39AM
Jan-06-23 07:04AM
Dec-21-22 05:07PM
Dec-19-22 08:11AM
(Zacks Small Cap Research)
Dec-15-22 08:30AM
Dec-13-22 07:00AM
Nov-14-22 09:25AM
(Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM
Oct-31-22 11:13AM
08:58AM
07:00AM
Oct-26-22 04:01PM
07:00AM
Sep-13-22 07:00AM
Aug-10-22 06:40AM
(Zacks Small Cap Research)
Aug-04-22 07:00AM
Jul-11-22 07:23AM
(Zacks Small Cap Research)
Jun-30-22 06:21PM
Jun-28-22 06:29AM
Jun-27-22 04:01PM
Jun-02-22 07:00AM
May-27-22 08:12AM
(Zacks Small Cap Research)
May-10-22 07:00AM
Apr-26-22 04:30PM
Apr-25-22 10:20AM
(Zacks Small Cap Research)
Apr-08-22 01:00PM
Mar-10-22 04:05PM
Mar-09-22 11:34PM
Mar-08-22 04:30PM
Feb-04-22 05:16AM
(Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM
Jan-19-22 07:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-11-21 05:38AM
Dec-08-21 09:38AM
Nov-22-21 09:20AM
(Zacks Small Cap Research)
Nov-18-21 07:00AM
Nov-08-21 07:00AM
Oct-28-21 04:05PM
Oct-19-21 01:21PM
Oct-07-21 10:25AM
09:00AM
06:30AM
Aug-31-21 04:05PM
Aug-24-21 06:30AM
(Zacks Small Cap Research) +6.93%
Aug-16-21 02:32PM
12:13PM
10:22AM
07:00AM
Jul-13-21 12:38PM
May-25-21 07:00AM
May-10-21 10:59AM
(Zacks Small Cap Research)
May-06-21 07:01AM
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Glickman Richard M Director Apr 24 '24 Option Exercise 4.90 3,750 18,375 43,240 Apr 25 10:35 AM Virsik Peter Chief Operating Officer Apr 05 '24 Sale 7.94 694 5,510 11,940 Apr 05 06:16 PM Virsik Peter Chief Operating Officer Mar 05 '24 Sale 8.98 694 6,232 12,634 Mar 05 06:50 PM Virsik Peter Chief Operating Officer Feb 06 '24 Option Exercise 3.23 72,782 235,086 86,110 Feb 07 11:29 AM Virsik Peter Chief Operating Officer Feb 06 '24 Sale 10.29 72,782 748,927 13,328 Feb 07 11:29 AM Virsik Peter Chief Operating Officer Feb 05 '24 Option Exercise 3.23 500 1,615 13,828 Feb 06 08:27 AM Virsik Peter Chief Operating Officer Feb 05 '24 Sale 9.58 1,194 11,440 13,328 Feb 06 08:27 AM Virsik Peter Chief Operating Officer Jan 16 '24 Option Exercise 3.23 1,718 5,549 15,740 Jan 17 08:57 PM Virsik Peter Chief Operating Officer Jan 16 '24 Sale 10.01 1,718 17,197 14,022 Jan 17 08:57 PM Virsik Peter Chief Operating Officer Jan 05 '24 Sale 6.11 699 4,271 14,022 Jan 08 08:06 PM Parkinson David Ross Chief Executive Officer Dec 14 '23 Buy 2.30 9,223 21,213 65,675 Dec 18 09:57 PM BERGER FRANKLIN M Director Nov 21 '23 Buy 5.73 23,259 133,274 784,404 Nov 22 06:22 PM BERGER FRANKLIN M Director Nov 03 '23 Buy 5.99 16,471 98,661 760,875 Nov 16 05:45 PM BERGER FRANKLIN M Director Nov 02 '23 Buy 5.35 60,000 321,000 744,404 Nov 16 05:45 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite